Takeda’s HYQVIA reduces CIDP relapse rates, Phase 3 trial reveals
Takeda Pharmaceutical Company has disclosed successful outcomes from its critical Phase 3 ADVANCE-CIDP 1 trial, focused on evaluating HYQVIA as a maintenance therapy for adults ... Read More